The influence of glatiramer acetate on Th17-immune response in multiple sclerosis-Reference-Cited by-同舟云学术

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis

Published:2020-10-30 Issue:10 Volume:15 Page:e0240305
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Melnikov Mikhail^ORCID,Sharanova Svetlana,Sviridova Anastasiya,Rogovskii Vladimir,Murugina Nina,Nikolaeva Anna,Dagil Yulia,Murugin Vladimir,Ospelnikova Tatiana,Boyko Alexey,Pashenkov Mikhail

Funder

Joint-stock company BIOCAD

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference50 articles.

1. Copaxone (glatiramer acetate injection) for subcutaneous use [package insert] Teva Pharmaceuticals, North Wales, PA, January 2014.

2. Demonstration of equivalence of a generic glatiramer acetate (Glatopa™);J Anderson;J Neurol Sci,2015

3. The mechanism of action of glatiramer acetate treatment in multiple sclerosis;MK Racke;Neurology.,2010

4. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.;O Neuhaus;Proc Natl Acad Sci USA.,2000

5. Induction of CD4+CD25+ regulatory T cells by copolymer I through activation of transcription factor Foxp3;J Hong;Proc Natl Acad Sci U S A,2005

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum Concentrations of Chemokines CCL20, CXCL8 and CXCL10 in Relapsing-Remitting Multiple Sclerosis and Their Association with Presence of Antibodies against Epstein–Barr Virus;International Journal of Molecular Sciences;2024-07-24

2. Re-establishing immune tolerance in multiple sclerosis: focusing on novel mechanisms of mesenchymal stem cell regulation of Th17/Treg balance;Journal of Translational Medicine;2024-07-15

3. N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial;Journal of Neuroinflammation;2023-09-13

4. Therapeutic potential of targeting IL-17 and its receptor signaling in neuroinflammation;Drug Discovery Today;2023-04

5. Current Updates on the Diagnosis and Management of Multiple Sclerosis for the General Neurologist;Journal of Clinical Neurology;2023